{"id":"jte-451-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303719","moleculeType":"Small molecule","molecularWeight":"524.45"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"P2X7 is an ATP-gated ion channel expressed on immune cells that plays a role in inflammasome activation and cytokine release. By blocking P2X7, JTE-451 reduces excessive immune activation and inflammatory signaling, potentially beneficial in inflammatory and autoimmune conditions. This mechanism targets the purinergic signaling pathway involved in innate immunity.","oneSentence":"JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:57:38.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT03832738","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2019-01-17","conditions":"Plaque Psoriasis, Psoriasis, Skin Diseases","enrollment":152},{"nctId":"NCT03018509","phase":"PHASE1","title":"Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2016-12","conditions":"Plaque Psoriasis, Psoriasis, Skin Diseases","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"JTE-451 Tablets","genericName":"JTE-451 Tablets","companyName":"Akros Pharma Inc.","companyId":"akros-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses. Used for Inflammatory bowel disease, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}